Seth Lederman, Tonix Pharmaceuticals CEO
Small, struggling biotech winds up with a 3X loser as another PhIII of its lead drug collapses
Little Tonix Pharmaceuticals has run into another brick wall as its lead drug — a reformulated muscle relaxant originally approved 44 years ago — has failed another …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.